We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Industry Expresses Concern Over FDA’s Proposal Limiting Information on Off-Label Uses
Industry Expresses Concern Over FDA’s Proposal Limiting Information on Off-Label Uses
The pharmaceutical industry is worried the FDA will hinder the distribution of valid scientific information on off-label drug uses in its new proposal detailing what literature sales reps can distribute to physicians.